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Abstract
Background: To assess the possibility of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein
(HIP/PAP) as a biological marker for detecting Bladder cancer (BCa), we examined the expression of HIP/PAP in both
BCa specimens and BCa cell lines and measured HIP/PAP levels in urine from patients with BCa.
Methods: HIP/PAP expression in BCa samples was evaluated by western blot analysis, and urinary levels of HIP/PAP
in patients with BCa were measured by enzyme-linked immunosorbent assay. Urine samples were collected from
10 healthy volunteers and 109 with benign urological disorders as controls, and from 101 patients who were
diagnosed with BCa.
Results: HIP/PAP was highly expressed in BCa samples as compared with control bladder. Urinary HIP/PAP
concentrations were significantly higher in BCa patients than in controls (median value; 3.184 pg/mL vs. 55.200
pg/mL, P <0.0001, by Mann–Whitney U test). Urinary HIP/PAP levels in BCa patients correlated positively with
pathological T stages and progression-risk groups among non-muscle invasive BCa (P = 0.0008, by Kruskal-Wallis
test). Regarding the recurrence-risk classifications of non-muscle invasive BCa, the urinary levels of HIP/PAP were
significantly higher in the intermediate than in the low risk group (P = 0.0002, by Mann–Whitney U test). Based on a
cut-off of 8.5 pg/mL, the ability of urinary HIP/PAP levels to detect BCa had a sensitivity of 80.2%, specificity of
78.2%, positive predictive value (PPV) of 75.7%, and negative predictive value (NPV) of 82.3%.
Conclusions: HIP/PAP was abundantly expressed in BCa, and the urinary levels of HIP/PAP could be a novel and
potent biomarker for detection of BCa, and also for predicting the risks of recurrence- and progression-risk of
non-muscle invasive BCa. A large scale study will be needed to establish the usefulness of this biomarker.
Keywords: Bladder cancer, Urinary marker, HIP/PAP, ELISA, ROC
Background
Urothelial carcinoma is the most common Bladder can-
cer (BCa). In 2008, an estimated 38,6300 cases were
newly diagnosed with bladder cancer and there were
150,200 deaths due to bladder cancer worldwide. [1]
Early detection of primary and recurrent bladder cancers
may greatly reduce the mortality rate. The cystoscopic
examination is a feasible procedure for detection of BCa.
However, the examination is invasive for patients. On
the other hand, urine cytology is the most widespread
method for identifying BCa noninvasively despite its low
sensitivity for detecting low grade BCa. [2] In recent
years, numerous urine-based bladder tumor markers, in-
cluding bladder tumor antigen (BTA) and nuclear matrix
protein 22 (NMP22), have been reported as powerful
tools for the detection of BCa. In particular, NMP22 has
been widely used as a urine marker for BCa of good sen-
sitivity in comparison with urine cytology. Numerous
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studies have demonstrated that NMP22 has a superior
sensitivity (46–88% and 40–85%, respectively) to urine
cytology. [3] However, there remain differences among
reports yet, and the sensitivity is not fully satisfactory.
A protein called regenerating gene/regenerating islet-
derived (Reg) was originally identified in regenerating
pancreatic islet cells. [4] To date, several Reg family pro-
teins have been identified and described under various
nomenclatures such as pancreatitis-associated protein
(PAP) and hepatocarcinoma-intestine-pancreas (HIP).
They are broadly categorized into four groups, namely,
type I to IV. [5,6] In humans, six gene products, Reg-Iα,
Reg-Iβ, Reg-III (corresponding to Reg-IIIα in the
mouse), HIP/PAP (corresponding to Reg-IIIβ in the
mouse), Reg-IIIγ and Reg-IV have been identified. [7,8]
These members have been shown to be secretory pro-
teins that play a key role in both tissue regeneration and
inflammation in digestive organs. [9-11] Some of them
are also highly expressed in some cancers and function
as proliferative, tropic or anti-apoptotic factors in cancer
cells. [10,12] From the aspect of their characteristics as
secretory proteins, the examination of Reg family pro-
teins in body fluids (e.g., serum, urine) may contribute
to the detection of various cancers. [13-17] In fact Reg-
IV was demonstrated to be a potent screening marker
for gastric and pancreatic cancer. [18,19] Furthermore,
proteomic screening revealed urinary levels of Reg-I to
be a potential marker for BCa [20].
We previously reported that the interstitial cystitis
(IC) induced expression of some Reg family members in
Cyclophosphamide-induced cystitis model of rat, and
demonstrated that PAP-III (Reg-IIIγ in humans) was
expressed in the urothelium of the bladder and, on the
other hand, that PAP-I (HIP/PAP in humans) was
expressed in primary afferent neurons of dorsal root
ganglia that innervate the bladder. [21] Recently, we also
reported urinary levels of HIP/PAP to be significantly
higher in painful bladder syndrome (PBS)/IC patients
than in healthy controls. [22] Furthermore, protein ex-
pression of HIP/PAP was very high in the bladder
urothelium of PBS/IC patients. [22] In this study, based
on these findings, we investigated the possibility of high
levels of HIP/PAP in urine from BCa patients, and
revealed a possibility of urinary HIP/PAP as a diagnostic
biomarker of BCa. We also evaluated the diagnostic ac-
curacy of urinary HIP/PAP as compared with conven-
tional markers, such as urinary NMP22 and BTA.
Methods
Patients and samples
We followed our institution’s ethics guidelines and the study
was approved by the ethics committee of Osaka City Univer-
sity Hospital. All patients provided informed consent.
Urine samples were collected from 10 healthy volun-
teers and 109 with benign urological disorders as controls,
and from 101 patients who were diagnosed with BCa at
Osaka City University Hospital between 2008 and 2011
(Table 1). Voided urine samples were collected into a
sterile container at the urological section. Both urinary
NMP-22 and BTA levels were measured and the cytology
was examined using freshly voided urine immediately after
the samples were obtained. The rests kept at 4°C. They
were transported to our laboratory and centrifuged at
800 × g for 10 minutes. The supernatants were stored
at -80°C until the following analyses were performed.
Tumor tissues were collected after transurethral resec-
tion, and cystectomy. As a control tissue, normal bladder
was collected from patients who had undergone cystectomy
Table 1 Patient characteristics
BCa
Total number 101
Median age (range) (years) 70.3(49-88)
Sex
Male 75
Female 26
T-category
Ta 48
T1 21
T2 16
≧T3 12
Grade
G1 8
G2 54
G3 25
Controls
Total number 119
Median age (range) (years) 60.2(29-84)
Sex
Male 86
Female 33
Healthy volunteers 10
Benign urological disease 109
BPH 41
LOH syndrome 29
NGB 18
Urolithiasis 8
Severe cystisis 6
Renal cysts 5
Nutcracker syndrome 2
Total numbers of the patients do not always add up to 101 because clinical
information was incomplete for some individuals.
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for localized BCa. The collected specimens were immedi-
ately frozen and stored at -80°C in a freezer.
Cell lines and cell culture
Human bladder cancer cell lines T24, TCCSUP, RT4,
HT1376 and UMUC-3 were obtained from the Ameri-
can Type Culture Collection (Manassas, VA, USA). All
cell lines were maintained in RPMI 1640 (Sigma, St.
Louis, MO, USA) supplemented with 10% fetal bovine
serum, 100 U/mL of penicillin and 100 μg/mL of
streptomycin (Gibco, New York, USA) at 37°C in a hu-
midified atmosphere containing 5% CO2.
Western blotting
Tumor and normal tissue samples were homogenized in
lysis buffer containing 40 mM Tris base, 8 M urea and
2% CHAPS, and centrifuged at 10,000× g for 20 min
at 4°C. The supernatants were aliquoted and stored at
-80°C after measurement of protein concentrations. Cells
were harvested and whole-cell lysate were prepared using
the PRO-PREP protein extraction solution (iNtRON Bio-
technology, Gyeonggi-do, Korea) in accordance with the
manufacturer’s instructions. Protein samples (100 μg of
each protein) were treated at 55°C for 10 min in 2% SDS-
treating solution containing 5% β-mercaptoethanol and
separated in 10% SDS-polyacrylamide gels and trans-
ferred onto nitrocellulose membranes. Membranes were
blocked for 1 h at room temperature with Tris-buffered
saline (TBS) containing 0.05% Tween 20 and 1% BSA,
and incubated overnight at 4°C with the following pri-
mary antibodies; anti-HIP/PAP (1:400 dilution) [23] and
anti-β-actin (1:8000 dilution, Abcam, Cambridge, UK).
Immunoblots were washed with TBS containing 0.05%
Tween 20 and incubated with secondary antibodies con-
jugated with horseradish peroxidase anti-mouse IgG or
anti-rabbit IgG (Santa Cruz Biotechnology, Santa Cruz,
CA, USA) for 1 h at room temperature. Immunoreactive
proteins were visualized using the ECL detection system
(Pierce, Rockford, IL,USA).
Enzyme-linked immunosorbent assay (ELISA) for urinary
HIP/PAP
Urinary HIP/PAP concentrations were measured by
ELISA (Dynabio, Marseille, France). Urine samples were
pipette into wells precoated with anti-HIP/PAP antibody
according to the manufacturer’s instructions. After incu-
bation for 3 hours at room temperature, the plates were
rinsed with washing buffer. They were then incubated
with biotinylated anti-HIP/PAP antibody. The plates
were rinsed, incubated with avidin-peroxidase, and
developed with tetramethylbenzidine substrate. Develop-
ment was stopped with sulfuric acid, and absorbance at
450 nm was determined with an automatic plate reader.
To examine the cross-reactivates of this kit, Reg-Iα
(Abcam Ltd., Cambridge, UK), Reg-Iβ (Abcam Ltd.) and
Reg-IV (R&D Systems, MN, USA) were measured.
Measurement of urinary NMP-22 and BTA
Both urinary NMP 22 and BTA levels are measured in
freshly voided urine samples. Measurement of urinary
NMP-22 levels was requested of SRL, Inc. (Tokyo,
Japan) and followed by measurement with the UNMP-
22 test kit (Inverness Medical Japan, Tokyo, Japan). The
cut-off value was 12.0 U/mL. Evaluation of urinary BTA
levels was also requested of SRL, Inc. and followed by
measurement with the BTA kit (TFB Inc,Tokyo, Japan).
The BTA test is a latex agglutination assay for qualitative
detection in urine.
Statistical analysis
Mann–Whitney U test nonparametric analysis was per-
formed for comparison of urinary HIP/PAP concentra-
tions between two groups. The Kruskal-Wallis test was
performed for comparison of urinary HIP/PAP concen-
trations among three or more different groups. P-values
less than 0.05 were considered statistically significant.
Receiver operating curve (ROC) analyses were used to
define the optimal diagnostic cut-off as well as the diag-
nostic performance given by the area under the curve
Figure 1 Expression of HIP/PAP protein in tissue samples and BCa cells. (A) Expression of HIP/PAP protein in a normal bladder tissue and
BCa specimens. (B) Expression of HIP/PAP protein in human BCa cell lines. Protein samples were prepared from each specimen and cell line and
then analyzed by western blotting using anti-HIP/PAP antibody to detect HIP/PAP protein (upper panel). To demonstrate equal loading amounts
of samples, western blotting using anti-β-actin antibody was also performed (lower panel).
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(AUC). JMP software (version 9.0.0; SAS Institute Inc,
Cary, NC) was used for statistical analyses.
Results
HIP/PAP expression in the BCa specimens and BCa cell
lines
As shown in Figure 1A, western blot analysis using the
anti-HIP/PAP antibody revealed that the expression of
HIP/PAP protein was detectable in BCa samples. On the
other hand, HIP/PAP protein expression was not
detected in a normal bladder tissue (Figure 1A). Further-
more, HIP/PAP was highly expressed in five BCa cell
lines derived from low grade (RT4), high grade
(HT1376), invasive (T24, UM-UC-3) and metastatic
(TCCSUP) tumors (Figure 1B).
Urinary HIP/PAP levels in relation to the pathological
grade of BCa
Urinary levels of HIP/PAP in both BCa patients and
controls were measured using the HIP/PAP ELISA sys-
tem. Because Reg family members have highly similar
structures, we initially examined whether the ELISA sys-
tem cross-reacted with other family members such as
Reg-Iα, -Iβ, and -IV, whose expressions were previously
reported in some malignant tissues. [13,16,18-20] The
ELISA system detected only HIP/PAP and had no or al-
most negligible cross-reactivity with other human family
members (Figure 2). As shown in Figure 3A, the urinary
HIP/PAP concentration in the BCa group was signifi-
cantly higher than that in controls (median value; 3.184
pg/mL vs. 55.200 pg/mL, P < 0.0001). There was a sig-
nificant positive correlation between urinary HIP/PAP
levels in BCa patients and their pathological T stages
(Ta, T1, T2, ≥ T3) (P < 0.0001) (Figure 3B).
Urinary HIP/PAP levels in relation to recurrence-risk and
progression-risk classifications of non-muscle invasive
BCa
Recurrence-risk and progression-risk scores are calculated
for each patient according to the European Organisation
for Research and Treatment of Cancer (EORTC) defin-
ition. These factors comprise tumor grade, tumor stage,
tumor size, numbers of tumor, earlier recurrence rate, and
the presence of carcinoma in situ. Based on these scores,
patients were considered to have low, intermediate, or
high risk for recurrence and progression. With regards to
the recurrence-risk classification of non-muscle invasive
BCa, urinary levels of HIP/PAP in the low risk group were
significantly lower than those in intermediate risk group
(P= 0.0002) (Figure 4A). In this study high recurrence-risk
group did not exist. Moreover, the levels of urinary HIP/
PAP showed a significant positive correlation with
progression-risk groups among non-muscle invasive BCa
cases (P= 0.0008) (Figure 4B). In particular, urinary levels
of HIP/PAP in the low progression-risk group were sig-
nificantly lower than those in the intermediate and high
progression-risk group (P= 0.0105 and P=0.0009, respect-
ively) (Figure 4B).
Comparison of sensitivity, specificity, positive predictive
value (PPV) and negative predictive value (NPV) of
urinary HIP/PAP with those of urinary NMP-22 and BTA
regarding the prediction of BCa
The possibility of urinary HIP/PAP levels predicting BCa
was evaluated by ROC analysis (Figure 5). As results of
this calculation, a cut-off of 8.5 pg/mL was determined
and the area under the ROC curve (AUC) was 0.863.
On the basis of this cut-off value, urinary HIP/PAP
levels showed a sensitivity of 80.2%, specificity of 78.2%,
PPV of 75.7%, and NPV of 82.3% (Table 2). On the con-
trary, urinary levels of NMP-22 and BTA showed sensi-
tivities of 52.1% and 34.7%, specificities of 93.5% and
96.1%, PPV of 89.3% and 91.7%, and NPV of 65.2% and
54.1%, respectively (Table 2). Though urine cytology had
a sensitivity of 38.8% (data not shown), we could not cal-
culate specificity, PPV and NPV because few control
patients underwent urine cytology.
Discussion
The gold standard for diagnosis of BCa is the cystos-
copy. However, the cystoscopy is an invasive procedure
for patients. Urine cytology is the most widely used con-
ventional method in predicting BCa. The sensitivity of
urine cytology is poor for detecting low grade BCa al-
though it is useful for detecting high grade BCa and car-
cinoma in situ. Therefore, identification of additional
potent urinary biomarkers are sought to establish earlier
detection of BCa.
Figure 2 Specificity of the HIP/PAP ELISA system. The ELISA
system had no or almost negligible cross-reactivity with Reg-Iα, -Iβ,
and -IV.
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Recently, Reg family proteins have been focused as
candidates of serum biomarkers for detecting some can-
cers. [13-19] To our knowledge, there are no prior
reports describing the expression of HIP/PAP in relation
to the occurrence of BCa. In this study, we demon-
strated HIP/PAP protein was significantly expressed in
BCa specimens and BCa cell lines but not in normal
bladder tissues (Figure 1). Furthermore, urinary levels of
HIP/PAP in BCa patients were significantly higher than
those in the control group including healthy volunteers
and patients with benign urological diseases (Figure 3A).
Interestingly, urinary levels of HIP/PAP also correlated
positively with bladder tumor size (T stage), recurrence-
and progression-risk classifications of non-muscle inva-
sive BCa (Figures 3B and 4). Although two previous
reports proposed that Reg-I could be a marker for BCa,
[20,24] the ELISA used in this study showed virtually no
cross-reactivates with Reg-Iα and -Iβ proteins (Figure 2),
indicating that the urinary signal detected in the ELISA
was HIP/PAP and not Reg-I. In this study, we investi-
gated six cases of non-interstitial severe cystitis patients
in the group of benign urological disease, and two in the
Figure 3 Urinary levels of HIP/PAP determined by the ELISA system. (A) Urinary HIP/PAP levels in BCa patients and controls. Bars represent
median levels. The median urinary HIP/PAP concentration in BCa patients (median: 55.20 pg/mL, 25th and 75th percentiles: 11.91 and 150.96) was
significantly higher than that in controls (median: 3.18 pg/mL, 25th and 75th percentiles: 0.00 and 8.28) (Mann–Whitney U test, P <0.0001).
Asterisk indicates statistically significant P-values (P <0.05). (B) Correlation of urinary HIP/PAP levels in BCa patients with pathological stage.
Patients were divided into four groups (Ta,T1,T2, ≥T3). The levels of urine HIP/PAP correlated proportionally with progression of T stage
(Kruskal-Wallis test, P < 0.0001).
Figure 4 Urinary HIP/PAP levels in relation to recurrence-risk and progression-risk classifications of non-muscle invasive BCa. (A)
Urinary levels were significantly higher in the intermediate risk group than in the low recurrence-risk group of non-muscle invasive BCa
(Mann–Whitney U test, P = 0.0002). (B) Urinary HIP/PAP levels correlated significantly with increased risk of progression in non-muscle invasive
BCa cases (Kruskal-Wallis test, P = 0.0008).
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six cases were false positive. Similar to the cases of other
urinary markers such as NMP-22 and BTA, the false
positive for HIP/PAP may be possibly identified in
patients with benign inflammatory conditions. In
addition, to eliminate the potential impact of hematuria
in this ELISA kit, we investigated two cases of patients
with Nutcracker syndrome in the group of benign uro-
logical disease. Although the above two patients had
gross hematuria, the concentration of HIP/PAP in the
urine of both two cases was less than 8.5 pg/mL. We
therefore assume that this ELISA kit is not affected by
hematuria.
Approximately 80% of newly-diagnosed BCa patients
have non-muscle invasive tumors. [25] Regardless of
endoscopic complete resection of such tumors, about
50% and 15% of these cases have the possibility of recur-
rence and progression within 5 years, respectively. [26]
The 5-year overall survival (OS) of patients with non-
muscle invasive BCa ranges from 82% to 95%, whereas
that of cases with muscle invasion is only 50%. [27-29]
Therefore, both diagnosis of BCa at an early stage and
strict surveillance after initial treatments are crucial for
improving the outcomes of BCa patients. According to
the EORTC risk criteria for non-muscle invasive BCa,
patients treated with an initial transurethral tumor re-
section are divided into groups at low, intermediate, and
high risk for recurrence and progression. The current
study showed urinary HIP/PAP levels in the intermedi-
ate recurrence-risk group to be significantly higher than
those in the low recurrence-risk group (Figure 4A). Fur-
thermore, urinary HIP/PAP levels correlated positively
with the grade of progression-risk groups (low, inter-
mediate, high) (Figure 4B). On the basis of these results,
pre-treatment urinary HIP/PAP levels may be applied as
a prognostic factor for recurrence and progression of
non-muscle invasive BCa. On the other hand, the reli-
ability of predictive biomarkers is attributed to high PPV
and NPV. However, routine urinary markers (e.g., NMP-
22, BTA) are not sufficiently accurate to detect BCa. As
shown in Figure 5, the AUC of HIP/PAP and NMP-22
on ROC analysis were 0.863 (95% CI, 0.814-0.912) and
0.729 (95% CI, 0.655-0.803), respectively. This suggests
that urinary HIP/PAP could be a better urinary marker
for BCa than the urinary NMP-22. Furthermore, as
shown in Table 2, the statistical analysis to estimate the
precisions of the three urinary markers revealed that
HIP/PAP was superior to NMP-22 and BTA in terms of
sensitivity (80.2% vs. 52.1% and 34.7%) and NPV (82.3%
vs. 65.2% and 54.1%). This characteristic of urine HIP/
PAP may be useful for reducing false negative cases of
suspected BCa. In particular, it may contribute to strict
follow-up for higher risk groups (e.g., intermediate and
high) among non-muscle invasive BCa. However, false
positive cases may undergo unnecessary endoscopic
examination due to the low PPV of HIP/PAP. Based on
the potential of current urinary markers, we propose
that examinations combining a number of urinary bio-
markers would provide a higher accuracy in predicting
BCa.
Conclusions
Urinary HIP/PAP is considered to be a potentially useful
urinary marker for early detection of BCa or predicting
recurrence and progression after an initial therapy for
non-muscle invasive BCa. A large scale study will be
needed to establish the usefulness of this biomarker.
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Figure 5 Ability of urinary levels of HIP/PAP and NMP-22 to
predict BCa using ROC analysis. The AUC of HIP/PAP and NMP-22
were 0.863 (95% CI, 0.814-0.912) and 0.729 (95% CI, 0.655-0.803),
respectively.
Table 2 Sensitivity, specificity, PPV and NPV of urine
markers HIP/PAP, NMP22 and BTA
HIP/PAP [95% CI] NMP-22 [95% CI] BTA [95% CI]
Sensitivity (%) 80.2 [71.4 - 86.8] 52.1 [42.2 - 61.8] 34.7 [25.9 – 44.7]
Specificity (%) 78.2 [69.9 - 84.6] 93.5 [86.5 - 97.0] 96.1 [89.0 - 98.6]
PPV (%) 75.7 [66.8 - 82.8] 89.3 [78.5 - 95.0] 91.7 [78.2 - 97.1]
NPV (%) 82.3 [74.2 - 88.2] 65.2 [56.7 – 72.7] 54.1 [45.7 – 62.3]
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